In just five days, a lot of future doctors will learn where they will do their first doctoring —
Each year, at precisely the same moment – noon on the east coast, 9 a.m. on the west – thousands of graduating medical school students across the country simultaneously tear open an envelope. Inside, there is a single sheet of paper and on it, a handful of words. Those words will inform each graduate where he or she will do their residencies, where each will spend the first several years of their careers as working doctors.
It’s called Match Day. Started in 1952 and operated by the non-profit National Resident Matching Program, the event culminates months of applications and interviews by fourth-year medical school students, each of whom may have visited a dozen or more hospitals and institutions across the country in search of their perfect match. … Read the Full Story from the UC San Diego Newsroom
Tapping the potential of metabolomics, an emerging field focused on the chemical processes of metabolism, researchers at University of California, San Diego School of Medicine have identified a new and pivotal player in diabetic kidney disease.
The study, published online July 22 in the Journal of the American Society of Nephrology, also clarifies a central mechanism of action in diabetic kidney disease that is generating considerable excitement among researchers and the biopharmaceutical community. The mechanism, involving the NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (NOX) proteins, NOX1 and NOX4, is now the subject of a phase II clinical trial for the treatment of diabetic kidney disease. … Read the Full Story from the UC San Diego News Center
Senior author of the study report is Kumar Sharma, MD, FAHA, professor of medicine in the Division of Nephrology and director of the Center for Renal Translational Medicine at UC San Diego School of Medicine.
Study adds credence to new treatment approach now in clinical trials —
Researchers at the University of California, San Diego School of Medicine have demonstrated a direct connection between two signaling proteins and liver fibrosis, a scarring process underlying chronic liver disease, the 12th leading cause of death in the United States.
The finding adds further credence to a current pharmaceutical effort to create new treatments for diabetic nephropathy, liver fibrosis and other progressive fibrotic and inflammatory diseases, based on blocking these two molecules, both members of the NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (NOX) family of proteins. … Read the Full Story from the UC San Diego News Center
Senior author of the study report is David A. Brenner, MD, vice chancellor for health sciences, dean of UC San Diego School of Medicine and professor in the Division of Gastroenterology. The report was published online in PLOS ONE on July 29.
Novel treatment has 97 percent success rate in co-infected patients —
Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV. … Read the full story from the UC San Diego News Center
Wyles D.L., Ruane P.J., Sulkowski M.S., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal of Medicine July 21, 2015, 10.1056/NEJMoa1503153. Free full text